CTLA4 and hepatocellular carcinoma: A notable example is the HIMALAYA trial in advanced hepatocellular carcinoma, where the combination of durvalumab and the anti‐CTLA‐4 agent tremelimumab obtained a 5‐year OS rate of 19.6% [23], further confirming the capacity of immunotherapy to induce long‐lasting survival benefits, consistent with findings in Non–Small‐Cell Lung Cancer and melanoma [19, 20, 21].